resTORbio to Present at the 2018 RBC Capital Markets Global Healthcare Conference
A live webcast of the presentation can be accessed on the Investors section of resTORbio’s website at http://ir.restorbio.com/investors.
resTORbio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. resTORbio’s lead program focuses on selective inhibition of the target of rapamycin complex 1 (TORC1) pathway to treat aging-related diseases with an initial focus on diseases caused by immunosenescence, the decline in immune function that occurs during aging.
Stern Investor Relations, Inc.